
    
      The purposes of this study are:

        1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed
           patients (by using candidate gene approach and whole genome scanning)

        2. To improve the success rate of escitalopram treatment response for depressed patients
    
  